Back to Interventions
Substance / Medication

Eptifibatide

SNOMED 386998009UMLS C0253563

Overview

Active Ingredient
eptifibatide
RxNorm CUI
75635
Labeler: Slate Run Pharmaceuticals, LLCUpdated: 2026-02-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Preinfarction syndrome
Myocardial infarction
Impending infarction

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Cholesterol

LOINC 2093-3

secondary

Creatine kinase isoenzymes

LOINC 13969-1

primary

Troponin T.cardiac

LOINC 6598-7

primary

Research Evidence

Published studies and systematic reviews

Sort:
Safety and efficacy of adjunctive tirofiban and eptifibatide in acute ischemic stroke: A systematic review and meta-analysis.
Ali Hameer, Shehzad Rida, Ahmed Usama et al. · J Stroke Cerebrovasc Dis · 2026
PMID: 41500359Meta-Analysis
Eptifibatide as an adjuvant therapy to thrombolysis versus thrombolysis alone in stroke management: a systematic review and meta-analysis of randomized controlled trials.
Carretta Lucca Tamara Alves, Gonçalves Ocílio Ribeiro, Almeida Luiz Guilherme Silva et al. · J Thromb Thrombolysis · 2025
PMID: 40544389Meta-Analysis
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.
Liu Jingting, Yang Yihong, Liu Hongbo · J Thromb Thrombolysis · 2022
PMID: 34780001Meta-Analysis
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Zhou Xiaoqin, Wu Xinyu, Sun Huan et al. · J Evid Based Med · 2017
PMID: 28449419Meta-Analysis
Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.
Roy Akash, Elm Jordan, Ingles James R et al. · Neurology · 2025
PMID: 41071964RCT
A Double-Blinded Randomized Controlled Trial Comparing Eptifibatide Bolus Only Versus Bolus Plus Infusion In Patients Undergoing Primary Percutaneous Coronary Intervention For ST-Elevation Myocardial Infarction.
Mousavi Mehdi, Sehati Fatemeh, Tayebi Amirhossein et al. · Cardiovasc Revasc Med · 2023
PMID: 36737382RCT
Intracoronary eptifibatide with vasodilators to prevent no-reflow in diabetic STEMI with high thrombus burden. A randomized trial.
Hamza Mohamed, Elgendy Islam Y · Rev Esp Cardiol (Engl Ed) · 2022
PMID: 35039226RCT
Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)-a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy.
Berthelsen Rasmus Ehrenfried, Ostrowski Sisse Rye, Bestle Morten Heiberg et al. · Crit Care · 2019
PMID: 31488213RCTFull text (PMC)
Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
Marian Moazez J, Alli Oluseun, Al Solaiman Firas et al. · J Am Heart Assoc · 2017
PMID: 28611098RCTFull text (PMC)
Immediate & Short Term Outcome of Using Single Bolus Eptifibatide in Percutaneous Coronary Intervention: A Randomized Control Study.
Ahsan S A, Haque K S, Arzu J et al. · Mymensingh Med J · 2017
PMID: 28588165RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X
Interventional Cardiology Physician

Internal Medicine — Interventional Cardiology

NUCC 207RI0011X
Find a Provider

Health Goals

Goals connected through associated conditions

Improve Cardiovascular Fitness

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eptifibatide (substance)
SNOMED CT
386998009
UMLS CUI
C0253563
RxNorm CUI
75635
Labeler
Slate Run Pharmaceuticals, LLC

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

3
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.